Clinical perspectives on xenobiotic-induced hepatotoxicity

Drug Metabolism Reviews

Volumn 36, Issue 2, 2004, Pages 301-312

  Gunawan, Basuki ^a   Kaplowitz, Neil ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Acute hepatitis; Cholestasis; Drug induced liver disease; Hepatotoxicity; Herbal supplements

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANDROGEN; AZATHIOPRINE; BOSENTAN; CHLORPROMAZINE; DACARBAZINE; DANTROLENE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROMYCIN; ESTROGEN; FELBAMATE; FLUCLOXACILLIN; KETOCONAZOLE; METHYLDOPA; MINOCYCLINE; NITROFURANTOIN; PEMOLINE; PHENYTOIN; SULFONAMIDE; SULINDAC; TERBINAFINE; TETRACYCLINE; TOLCAPONE; TRICYCLIC ANTIDEPRESSANT AGENT; TROGLITAZONE; TROVAFLOXACIN; UNINDEXED DRUG; VALPROIC ACID; ZALCITABINE; ZIDOVUDINE;

CHOLESTASIS; CHRONIC HEPATITIS; CHRONIC LIVER DISEASE; CLINICAL FEATURE; CONFERENCE PAPER; DIAGNOSTIC VALUE; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; ECONOMIC ASPECT; GRANULOMATOUS HEPATITIS; HEALTH CARE; HISTOPATHOLOGY; HUMAN; LEGAL ASPECT; LIVER DISEASE; LIVER TOXICITY; PROFESSIONAL PRACTICE; XENOBIOTIC METABOLISM;

ANIMALS; DIETARY SUPPLEMENTS; HEPATITIS, TOXIC; HUMANS; LIVER; LIVER FUNCTION TESTS; MEDICINE, HERBAL; XENOBIOTICS;

EID: 3042519582     PISSN: 03602532     EISSN: None     Source Type: Journal    
DOI: 10.1081/DMR-120034148     Document Type: Conference Paper

References (26)

1. Ballet, F. (1997). Hepatotoxicity in drug development: detection, significance and solutions. J. Hepatol. 26(suppl 2):26-36.
2. Benichou, C., Danan, G., Flahault, A. (1993). Causality assessment of adverse reactions to drugs-II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J. Clin. Epidemiol. 46(11):1331-1336.
3. Berardinis, V. E., Moulis, C., Maurice, M., Beaune, P., Pessayre, D., Pompon, D., Loeper, J. (2000). Human microsomal epoxide hydrolyase is the target of germander-induced autoantibodies on the surface of human hepatocytes. Mol. Pharmacol. 58:542-551.
4. Danan, G., Benichou, C. (1993). Causality assessment of adverse reactions to drugs-I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J. Clin. Epidemiol. 46 (11):1323-1330.
5. Degott, C., Feldmann, G., Larrey, D., Durand-Schneider, A. M., Grange, D., Machayeki, J. P., Moreau, A., Potet, F., Benhamou, J. P. (1992). Drug-induced prolonged cholestasis in adults: a histological semiquantitative study demonstrating progressive ductopenia. Hepatology 17:244-251.
6. Desmet, V. J. (1997). Vanishing bile duct syndrome in drug-induced liver disease. J. Hepatol. 26(Suppl. 1):31-35.
7. Estes, J. D., Stolpman, D., Olyaei, A., Corless, C. L., Ham, J. M., Schwartz, J. M., Orloff, S. L. (2003). High prevalence of potentially hepatotoxic herbal supplement use in patients with fulminant hepatic failure. Arch. Surg. 138:852-858.
8. Fau, D., Lekehal, M., Farrell, G., Moreau, A., Moulis, C., Feldman, G., Haouzi, D., Pessayre, D. (1997). Diterpenoids from germander, an herbal medicine, induce apoptosis in isolated rat hepatocytes. Gastroenterology 113:1334-1346.
9. Favreau, J. T., Mina, L. R., Braunstein, G., Orshansky, G., Park, S. S., Coody, G. L., Love, L. A., Fong, T. L. (2002). Severe hepatotoxicity associated with the dietary supplement LipoKinetix. Ann. Intern. Med. 136:590-595.
10. Graham, D. J., Green, L., Senior, J. R., Nourjah, P. (2003). Troglitazone-induced liver failure: a case study. Am. J. Med. 114:299-306.
11. Han, D., Matsumaru, K., Rettori, D., Kaplowitz, N. (2004). Usnic acid induced necrosis of cultured mouse hepatocytes: inhibition of mitochondrial function and oxidative stress. Biochem. Pharmacol 67:439-451.
12. Kaplowitz, N. (2001a). Drug-induced liver disorders: implications for drug development and regulation. Drug Safety 24(7):483-490.
13. Kaplowitz, N. (2001b). Causality assessment versus guilt by association in drug hepatotoxicity. Hepatology 33:308-310.
14. Kaplowitz, N. (2002a). Drug-induced hepatocellular injury and cholestasis. In: Mechanisms of Acute and Chronic Liver Disease: Implications for Diagnosis, Pathogenesis, and Treatment. American Association for the Study of Liver Diseases Postgraduate Course 2002. Boston, MA, Nov 1-2. Alexandria, VA: AASLD, pp. 79-86. Suchy, F. J., Fitz, J. G., Maher, J. J. Course Directors.
15. Kaplowitz, N. (2002b). Biochemical and cellular mechanisms of toxic liver injury. Semin. Liver Dis. 22(2):137-144.
16. Larrey, D., Vial, T., Pauwels, A., Castot, A., Biour, M., David, M., Michel, H. (1992). Hepatitis after germander (Teucrium chamaedrys) administration: another instance of herbal medicine hepatotoxicity. Ann. Intern. Med. 117 (2):129-132.
17. Lasser, K. E., Allen, P. D., Woolhandler, S. J., Himmelstein, D. U., Wolfe, S. M., Bor, D. H. (2002). Timing of new black box warnings and withdrawals for prescription medications. JAMA 287:2215-2220.
18. Lewis, J. D., Strom, B. L. (2002). Balancing safety of dietary supplements with the free market. Ann. Intern. Med. 136:616-618.
19. Liu, Z. X., Kaplowitz, N. (2002). Immune-mediated drug-induced liver disease. Clin. Liver Dis. 6:755-774.
20. Loeper, J., Descatoire, V., Letteron, P., Moulis, C., Degott, C., Dansette, P., Fau, D., Pessayre, D. (1994). Hepatotoxicity of germander in mice. Gastroenterology 106:464-472.
21. Lucena, M. I., Camargo, R., Andrade, R. J., Peres-Sanchez, C. J., Sanchez, F., Cuesta, D. L. (2001). Comparison of two clinical scales for causality assessment in hepatotoxicity. Hepatology 33:123-130.
22. Nierenberg, D. W. (2002). "Did this drug cause my patient's hepatitis?" and related questions. Ann. Intern. Med. 136(6):480-483.
23. Nolan, C. M., Goldberg, S. V., Buskin, S. E. (1999). Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. JAMA 228(23):2207-2208.
24. Ostapowicz, G., Fontana, R. J., Schiodt, F. V., Larson, A., Davern, T. J., Han, S. H. B., McCashland, T. M., Shakil, O., Hay, E., Hynan, L., Crippin, J. S., Blei, A. T., Samuel, G., Reisch, J., Lee, W. M., the U.S. Acute Liver Failure Study Group. (2002). Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann. Intern. Med. 137(12):947-954.
25. Watkins, P. B., Whitcomb, R. W. (1998). Hepatic dysfunction associated with troglitazone. N. Engl. J. Med. 338:916-917.
26. Zimmerman, H. (1999). Drug-induced liver disease. In: Schiff, E., Sorrell, M., Maddrey, W. Schiff's Diseases of Liver. 8th ed. Philadelphia, PA: Lippincott-Raven Publishers. pp. 973-1064.